However, conventional approaches face dual barriers: Deficient Immunologic Niches: >90% of tumor organoids contain only epithelial cancer cells, lacking critical immune components such as CD8+ T cells and tumor-associated macrophages (TAMs). This evidence concerns the gene CD8A and cancer.